FI111223B - Immuuniterapeuttinen käyttö - Google Patents

Immuuniterapeuttinen käyttö Download PDF

Info

Publication number
FI111223B
FI111223B FI963866A FI963866A FI111223B FI 111223 B FI111223 B FI 111223B FI 963866 A FI963866 A FI 963866A FI 963866 A FI963866 A FI 963866A FI 111223 B FI111223 B FI 111223B
Authority
FI
Finland
Prior art keywords
vaccae
tumor
eller
nctc
att
Prior art date
Application number
FI963866A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963866A (fi
FI963866A0 (fi
Inventor
Graham Arthur William Rook
John Lawson Stanford
Original Assignee
Stanford Rook Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Rook Ltd filed Critical Stanford Rook Ltd
Publication of FI963866A publication Critical patent/FI963866A/fi
Publication of FI963866A0 publication Critical patent/FI963866A0/fi
Application granted granted Critical
Publication of FI111223B publication Critical patent/FI111223B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI963866A 1994-03-30 1996-09-27 Immuuniterapeuttinen käyttö FI111223B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9406301A GB9406301D0 (en) 1994-03-30 1994-03-30 Immunotherapeutic agent and its use
GB9406301 1994-03-30
GB9500715 1995-03-29
PCT/GB1995/000715 WO1995026742A1 (en) 1994-03-30 1995-03-29 Immunotherapeutic agent and its use

Publications (3)

Publication Number Publication Date
FI963866A FI963866A (fi) 1996-09-27
FI963866A0 FI963866A0 (fi) 1996-09-27
FI111223B true FI111223B (fi) 2003-06-30

Family

ID=10752750

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963866A FI111223B (fi) 1994-03-30 1996-09-27 Immuuniterapeuttinen käyttö

Country Status (22)

Country Link
EP (1) EP0752870B1 (pt)
JP (1) JP4135190B2 (pt)
KR (1) KR100392582B1 (pt)
CN (1) CN1121874C (pt)
AP (1) AP9600861A0 (pt)
AT (1) ATE218355T1 (pt)
AU (1) AU699081B2 (pt)
BR (1) BR9507338A (pt)
CA (1) CA2186851C (pt)
CZ (1) CZ280196A3 (pt)
DE (1) DE69526935T2 (pt)
DK (1) DK0752870T3 (pt)
ES (1) ES2177638T3 (pt)
FI (1) FI111223B (pt)
GB (1) GB9406301D0 (pt)
HU (1) HU220858B1 (pt)
NO (1) NO964075L (pt)
NZ (1) NZ282863A (pt)
PT (1) PT752870E (pt)
RU (1) RU2139728C1 (pt)
WO (1) WO1995026742A1 (pt)
ZA (1) ZA952644B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
AU730548B2 (en) * 1996-12-18 2001-03-08 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the TH2 activity of the immune system
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
WO2003063896A1 (en) * 2002-01-29 2003-08-07 Modi, Rajiv, Indravadan Process of preparing a pharmaceutical composition for immunity against tuberculosis in hiv positive individuals
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
NZ581806A (en) * 2004-06-07 2011-10-28 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
BG66067B1 (bg) * 2005-05-18 2011-01-31 Спартак ХАДЖИЕВ Средство с антитуморна активност на база бцж ваксина, метод за неговото получаване и използването му
US8557257B2 (en) 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
EP3235506B1 (en) 2010-07-26 2023-12-06 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
EP3319635B1 (en) * 2015-06-24 2021-04-21 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
ATE218355T1 (de) 2002-06-15
AU2078595A (en) 1995-10-23
PT752870E (pt) 2002-09-30
ES2177638T3 (es) 2002-12-16
FI963866A (fi) 1996-09-27
KR100392582B1 (ko) 2003-10-30
GB9406301D0 (en) 1994-05-25
EP0752870A1 (en) 1997-01-15
AP9600861A0 (en) 1996-10-31
MX9604401A (es) 1997-12-31
FI963866A0 (fi) 1996-09-27
AU699081B2 (en) 1998-11-19
HU9602661D0 (en) 1996-11-28
DE69526935T2 (de) 2002-09-19
CZ280196A3 (en) 1997-02-12
DE69526935D1 (de) 2002-07-11
HUT75835A (en) 1997-05-28
JPH09511737A (ja) 1997-11-25
JP4135190B2 (ja) 2008-08-20
CA2186851A1 (en) 1995-10-12
CN1121874C (zh) 2003-09-24
RU2139728C1 (ru) 1999-10-20
CN1150388A (zh) 1997-05-21
NZ282863A (en) 2001-06-29
KR970702057A (ko) 1997-05-13
ZA952644B (en) 1996-01-11
WO1995026742A1 (en) 1995-10-12
HU220858B1 (en) 2002-06-29
DK0752870T3 (da) 2002-07-15
NO964075L (no) 1996-11-25
EP0752870B1 (en) 2002-06-05
CA2186851C (en) 2008-11-18
NO964075D0 (no) 1996-09-27
BR9507338A (pt) 1997-09-16

Similar Documents

Publication Publication Date Title
FI111223B (fi) Immuuniterapeuttinen käyttö
Matsuzaki et al. Modulating immune responses with probiotic bacteria
Kohwi et al. Antitumor effect of Bifidobacterium infantis in mice
DE60032622T2 (de) Zusammensetzung und verfahren zur krebs-antigen-immuntherapie
AU691797B2 (en) Immunotherapeutic composition
CN107802831B (zh) 一种灭活乳酸菌疫苗佐剂
Lipton et al. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma
CA2064029C (en) Use of mycobacterium vaccae in the prevention of aids
KOHWI et al. Antitumor and immunological adjuvant effect of Bifidobacterium infantis in mice
UA79952C2 (en) MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
US6056964A (en) Immunotherapeutic agent and its use
US6090385A (en) Method of treating cancer
Minden et al. Suppression and immunotherapy of the guinea pig line-10 hepatocarcinoma mediated by nonviable Staphylococcus aureus
Halle-Pannenko et al. Comparison of various BCG preparations in the EORTC—ICIG experimental screening for systemic immunity adjuvants applicable to cancer immunotherapy
US6806253B2 (en) Immunodulatory complex and use thereof in helicobacter diseases
MXPA96004401A (es) Agente inmunoterapeutico y su uso
EP0657168B1 (en) Use of a TMA complex and/or a fragment of this TMA complex for the manufacturing of a medicament for the treatment and/or the prevention of cancer
BARBOUR et al. Induction of Early Immunopotentiation to Fimbriae of Salmonella Enteritidis (SE) by Administering Thymulin and Zinc to SE-Vaccinated Chicken Breeders
Buckspan et al. Immunoprophylaxis toward mammary carcinoma in mice immune to Listeria monocytogenes
Chander et al. A note: polyvalent radiovaccine against Salmonella
KR20010113691A (ko) Ｍ．배키를 이용한 만성 바이러스 감염의 치료
Mathews Antitumor effects of a variety of non-viable bacteria against the murine EL-4 lymphoma
Pistole et al. Purified Vi antigens as possible typhoid vaccines
Dazord et al. Increased resistance to tumor graft in mice infected by vaccinal strains of Brucella abortus
Averill et al. Cutaneous Immunization against B. aertrycke in the Guinea-Pig

Legal Events

Date Code Title Description
MA Patent expired